Skip to content
Clinical Trials – home

Institut Mutualiste Montsouris

Research site

France 42 Boulevard Jourdan, 75014 Paris, France

  • 33 trials recruiting
  • Prostate cancer · Gastric cancer · Colon cancer
  • Adults and children

About Specializations

Institut Mutualiste Montsouris in Paris, France specialises in clinical trials of conditions such as Prostate cancer, Gastric cancer, Colon cancer, Colorectal cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System and Gastrointestinal Oncology

At Institut Mutualiste Montsouris in Paris, a major share of the research is centered on digestive system diseases and gastrointestinal cancer. The trials explore new ways to improve treatment outcomes for conditions such as gastric cancer, colorectal cancer, pancreatic adenocarcinoma, and biliary tract cancer, with a strong focus on testing more effective therapies and refining perioperative and maintenance strategies.

  • Studies in gastric, esophageal, and gastroesophageal junction cancer are evaluating better treatment combinations and survival outcomes
  • Research in colorectal cancer includes personalized approaches, adjuvant care, and immunotherapy-based strategies
  • Trials in pancreatic cancer and biliary cancer are examining ways to improve disease control in advanced settings

Overall, the site’s gastroenterology expertise supports a broad program aimed at improving cancer care through more precise and effective treatment approaches.

Urologic and Prostate Cancer Research

This site has a strong focus on urologic cancers, especially prostate cancer, bladder cancer, and renal cell carcinoma. The clinical trials are designed to test new treatment combinations, improve outcomes after surgery, and identify better options for patients with localized, advanced, or metastatic disease.

  • Prostate cancer studies include hormone-based, targeted, and surgical approaches for localized and metastatic disease
  • Bladder cancer trials are evaluating immunotherapy and treatment strategies for high-risk and muscle-invasive disease
  • Renal cell carcinoma research is focused on adjuvant and advanced-disease treatment effectiveness

The research portfolio at Institut Mutualiste Montsouris highlights a strong commitment to improving survival, disease control, and quality of life in genitourinary oncology.

Gynecologic Oncology

Clinical research in gynecologic cancers covers ovarian cancer, endometrial cancer, and vulvar cancer. These studies are examining new treatment options for newly diagnosed, recurrent, and advanced disease, with the goal of improving survival and reducing the risk of relapse.

  • Ovarian, fallopian tube, and primary peritoneal cancer trials are testing improved first-line and maintenance strategies
  • Endometrial cancer research is focused on patients with mismatch repair deficiency and advanced disease
  • Vulvar cancer studies are exploring safer ways to manage early-stage disease while preserving treatment effectiveness

These investigations reflect an active effort to refine care for complex women’s cancers using more individualized treatment strategies.

Immune-Mediated and Inflammatory Diseases

The site also conducts research in immune system diseases and chronic inflammatory disorders, including Crohn’s disease, ulcerative colitis, giant-cell arteritis, and granulomatosis with polyangiitis. The trials aim to improve disease control, reduce complications, and evaluate better treatment effectiveness for patients living with long-term inflammatory conditions.

  • Inflammatory bowel disease research includes studies in Crohn’s disease and ulcerative colitis
  • Vasculitis trials are examining treatment options for giant-cell arteritis and granulomatosis with polyangiitis
  • These studies focus on better symptom control and improved long-term outcomes

This area shows that Institut Mutualiste Montsouris is not limited to oncology, but also contributes to research in chronic immune-related disease management.

Cardiovascular and Surgical Care

Research in cardiovascular diseases and surgical care includes studies on valvular heart disease, aortic conditions, post-operative atrial fibrillation, and transcatheter aortic valve implantation. These trials are aimed at improving surgical outcomes, preventing complications, and supporting safer recovery after cardiac procedures.

  • Trials in cardiac surgery are evaluating ways to lower post-operative complications
  • Valve disease research includes patients undergoing corrective procedures for tricuspid regurgitation and aortic stenosis
  • Studies also explore better prevention of rhythm problems after surgery

At this French hospital, cardiovascular research complements the broader clinical program by focusing on practical improvements in procedural care and recovery.

Metabolic, Infectious, and Other Clinical Research

The remaining trial portfolio spans several additional areas, including nutritional and metabolic diseases, bacterial infections, and broader diagnostic and therapeutic techniques. Research topics include type 2 diabetes remission after bariatric surgery, sepsis, candidemia, and Mycobacterium avium complex lung disease, with studies designed to improve treatment choices and clinical outcomes.

  • Metabolic disease research includes remission of type 2 diabetes after surgery
  • Infectious disease trials address sepsis, fungal bloodstream infection, and atypical mycobacterial lung disease
  • Some studies evaluate supportive care and prevention strategies in broader hospital practice

This diverse activity shows a wide-ranging clinical research environment at Institut Mutualiste Montsouris, with studies that address both specialized and everyday care needs.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
42 Boulevard Jourdan75014 ParisFrance
Recruiting now
33 trials
Conditions studied
59

More sites in ParisFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

82 clinical trials

Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Crohn's disease

Recruiting

One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Guselkumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Crohn's disease

Recruiting

A study testing how well mirikizumab works to achieve transmural healing in patients with Crohn's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Association Gercor

Study on the Effectiveness of BP1.4979 for Adult Men with Premature Ejaculation

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Centre Hospitalier Universitaire Rouen

Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Association Gercor

Study Comparing Apixaban and Carbasalate Calcium for Patients with Aortic Valve Replacement Due to Heart Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Assistance Publique Hopitaux De Paris

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Obinutuzumab for Patients with Relapsing Granulomatosis with Polyangiitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Regorafenib with Cyclophosphamide, Capecitabine, and Aspirin for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Regional Universitaire
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.